JP2009501735A - 魚類及び甲殻類における使用のための成長刺激ポリペプチド - Google Patents
魚類及び甲殻類における使用のための成長刺激ポリペプチド Download PDFInfo
- Publication number
- JP2009501735A JP2009501735A JP2008521780A JP2008521780A JP2009501735A JP 2009501735 A JP2009501735 A JP 2009501735A JP 2008521780 A JP2008521780 A JP 2008521780A JP 2008521780 A JP2008521780 A JP 2008521780A JP 2009501735 A JP2009501735 A JP 2009501735A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- growth
- fish
- polypeptides
- pichia pastoris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 105
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 105
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 103
- 230000012010 growth Effects 0.000 title claims abstract description 53
- 241000251468 Actinopterygii Species 0.000 title claims abstract description 35
- 241000238424 Crustacea Species 0.000 title claims abstract description 9
- 230000004936 stimulating effect Effects 0.000 title claims description 7
- 241000235058 Komagataella pastoris Species 0.000 claims abstract description 34
- 239000012228 culture supernatant Substances 0.000 claims abstract description 34
- 238000007654 immersion Methods 0.000 claims abstract description 14
- 230000004083 survival effect Effects 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 230000001418 larval effect Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 5
- 241000235648 Pichia Species 0.000 claims description 2
- 208000035240 Disease Resistance Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 210000005007 innate immune system Anatomy 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 abstract description 62
- 108010051696 Growth Hormone Proteins 0.000 abstract description 62
- 239000000122 growth hormone Substances 0.000 abstract description 62
- 230000000694 effects Effects 0.000 abstract description 36
- 241000276707 Tilapia Species 0.000 abstract description 28
- 108090000623 proteins and genes Proteins 0.000 abstract description 28
- 102000004169 proteins and genes Human genes 0.000 abstract description 20
- 230000014509 gene expression Effects 0.000 abstract description 15
- 230000001965 increasing effect Effects 0.000 abstract description 14
- 239000013604 expression vector Substances 0.000 abstract description 9
- 239000013598 vector Substances 0.000 abstract description 8
- 210000000987 immune system Anatomy 0.000 abstract description 5
- 239000003674 animal food additive Substances 0.000 abstract description 2
- 244000052769 pathogen Species 0.000 abstract description 2
- 235000019688 fish Nutrition 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 26
- 239000013642 negative control Substances 0.000 description 22
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 16
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 102000002265 Human Growth Hormone Human genes 0.000 description 9
- 108010000521 Human Growth Hormone Proteins 0.000 description 9
- 239000000854 Human Growth Hormone Substances 0.000 description 9
- 108010014251 Muramidase Proteins 0.000 description 9
- 102000016943 Muramidase Human genes 0.000 description 9
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 229960000274 lysozyme Drugs 0.000 description 9
- 239000004325 lysozyme Substances 0.000 description 9
- 235000010335 lysozyme Nutrition 0.000 description 9
- 230000036542 oxidative stress Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 241000277275 Oncorhynchus mykiss Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 102100036826 Aldehyde oxidase Human genes 0.000 description 5
- 102000016938 Catalase Human genes 0.000 description 5
- 108010053835 Catalase Proteins 0.000 description 5
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 241000252229 Carassius auratus Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 4
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000009360 aquaculture Methods 0.000 description 4
- 244000144974 aquaculture Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000005502 peroxidation Methods 0.000 description 4
- 230000006337 proteolytic cleavage Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 101150061183 AOX1 gene Proteins 0.000 description 3
- 241000252233 Cyprinus carpio Species 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101150009006 HIS3 gene Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- 241000277334 Oncorhynchus Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000006318 protein oxidation Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 241000238557 Decapoda Species 0.000 description 2
- 241000723298 Dicentrarchus labrax Species 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 102100020948 Growth hormone receptor Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 2
- 101710200814 Melanotropin alpha Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 2
- 241000340701 Oreochromis urolepis hornorum Species 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 2
- 241000277288 Salmo trutta Species 0.000 description 2
- 241000277331 Salmonidae Species 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150006240 AOX2 gene Proteins 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101710100586 Beta-fructofuranosidase, insoluble isoenzyme 2 Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 101710099093 Growth hormone receptor Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 101710195784 Invertase 2 Proteins 0.000 description 1
- 241000530454 Litopenaeus schmitti Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 101100335921 Mus musculus Gapt gene Proteins 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 208000025696 NK cell deficiency Diseases 0.000 description 1
- 241000277329 Oncorhynchus keta Species 0.000 description 1
- 241000276701 Oreochromis mossambicus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000490567 Pinctada Species 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 241000982698 Prorodonopsis coli Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241001063988 Rhabdosargus sarba Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000269809 Sparus aurata Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940096384 chicken egg white lysozyme Drugs 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000004007 growth hormone secreting cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- -1 saponin saponin Chemical class 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Insects & Arthropods (AREA)
- Birds (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
Abstract
Description
前記ポリペプチドを含む組換えピキア・パストリスMP36株の培養上清
ティラピアGHを含む組換えピキア・パストリスMP36株の培養上清
非形質転換ピキア・パストリスMP36株の培養上清を含むネガティブコントロール
未処置群
還元グルタチオン:GSHは酵素グルタチオンペルオキシダーゼの補因子である。これは酸化ストレスに対する防御機構のうちの1つである。我々は、群の間に統計的差異を認めなかった。しかしポリペプチド1及び2で処置した群において増大する傾向がある。
スーパーオキシドジスムターゼ:SODは抗酸化防御に属する酵素である。これはスーパーオキシド遊離ラジカルを捕捉する。我々は、群の間に統計的差異を認めなかった。ポリペプチド1及び2で処置した群において増大する傾向がある。
総オルガノペルオキシド:これは酸化促進系の要素の1つであり、ヒドロキシルラジカル前駆体の1つである。これは遺伝子発現の誘導物質、細胞機構の活性化物質並びにホスファターゼ及びキナーゼの調節物質でもあり得る。それは、生体異物の解毒に必要なグルタチオン−S−トランスフェラーゼの補因子でもある。群の間に統計的差異はない。
カタラーゼ:これは、生分子の酸化をもたらす酸化ストレスの指標である。カタラーゼのレベルが増大することは、グルタチオンペルオキシダーゼによって代謝され得ない遊離ラジカルが存在することを示唆する。実験開始から21日目において群の間に統計的差異はなかった。45日目で、対照と比較してポリペプチドで処置した群においてカタラーゼレベルが低下していた。
過酸化能:これは脂質酸化の指標である。我々は、ポリペプチド1及び2で処置した群において増大している傾向として、未処置群と比較して処置群において統計的有意差を得た。
タンパク質酸化:これはタンパク質酸化の指標である。我々は群の間に統計的差異を認めなかった。
本発明の主題であるポリペプチド及びティラピア成長ホルモンのコード配列を含有するピキア・パストリス発現ベクターの構築、MP36株への形質転換並びに該タンパク質の発現
前記ポリペプチドのコード配列は、あらかじめpR17ベクターにクローニングしたティラピアcDNAを鋳型として使用する特異的オリゴヌクレオチドでのPCRにより得た。ポリペプチド配列番号7のコード配列を増幅するために、我々は配列番号1及び配列番号2の配列に対応するオリゴヌクレオチドを使用した。ポリペプチド配列番号8のコード配列を増幅するためには、我々は配列番号3及び配列番号4の配列に対応するオリゴヌクレオチドを使用した。
該ポリペプチドを含有するP.パストリス培養上清での浸漬によるティラピアでの生育実験、免疫系への効果
実験は、1週間に3回90分間の浸漬により実施した。投与量は水1リットル当たり標的タンパク質0.1mgとした。実験群は以下の通りとした。:
1.ポリペプチド1を含有するP.パストリス培養上清で処置した群(処置1)
2.ポリペプチド2を含有するP.パストリス培養上清で処置した群(処置2)
3.ティラピアGHを含有するP.パストリス培養上清で処置した群(処置3)
4.非形質転換P.パストリス培養上清で処理したネガティブコントロール群(ネガティブコントロール)
5.未処置群
該ポリペプチドを含むピキア・パストリス培養上清での浸漬浴による金魚における生育刺激実験及び仔魚の品質の改善
4つの実験群を設計した。処置は、浸漬浴、1週間に3回90分間から成る。投与量は水1リットル当たり標的タンパク質0.1mgとした。実験群は、以下の通りとした。
1.ポリペプチド1を含むP.パストリス培養上清で処置した群(処置1)
2.ポリペプチド2を含むP.パストリス培養上清で処置した群(処置2)
3.ティラピアGHを含むP.パストリス培養上清で処置した群(処置3)
4.非形質転換P.パストリス培養上清で処置したネガティブコントロール群(ネガティブコントロール)
ポリペプチド1の種々の投与量での浸漬浴によるコイにおける生育実験
我々は、コイ仔魚の成長におけるポリペプチド1の種々の投与量での効果を検討した。4つの実験群を以下通り設計した。
1.ポリペプチド配列番号7を水1リットル当たりポリペプチド0.02mgの投与量で含むP.パストリス培養上清で処置した群(処置1)
2.ポリペプチド配列番号7を水1リットル当たりポリペプチド0.1mgの投与量で含むP.パストリス培養上清で処置した群(処置2)
3.ポリペプチド配列番号7を水1リットル当たりポリペプチド0.5mgの投与量で含むP.パストリス培養上清で処置した群(処置3)
4.未処置群
該ポリペプチドを含有するP.パストリス培養上清への浸漬による仔エビ、リトペナエウス・シュミッティ(Litopenaeus schmitti)における生育実験
3つの実験群を設計した。処置は、浸漬浴、1週間に3回1時間30分から成る。投与量は水1リットル当たり該タンパク質0.1mgとした。実験群は、以下の通りとした。
1.ポリペプチド配列番号7を含むP.パストリス培養上清で処置した群(処置1)
2.ポリペプチド配列番号8を含むP.パストリス培養上清で処置した群(処置2)
3.非形質転換P.パストリス培養上清で処理したネガティブコントロール群(ネガティブコントロール)
ポリペプチド配列番号7の種々の投与量での食餌投与によるティラピアにおける生育実験
我々は、開始時重量72.99±3.25gのティラピア稚魚の成長についてのポリペプチド配列番号7の2つの投与量での効果を測定した。試験を行った投与量は、餌1kg当たりポリペプチド配列番号7を4.8mg及び餌1kg当たりポリペプチド配列番号7を38.4mgとした。経口製剤は該ポリペプチドを含有するピキア・パストリス培養上清を基礎餌に混合することにより作製した。ネガティブコントロールは、非形質転換P.パストリス培養上清を加えた基礎餌を与えたティラピアとした。実験中、魚には1日2回、体重の5%に相当する量の餌を6週間与えた。
Claims (7)
- 以下の配列、配列番号7及び配列番号8のうちの1つに含まれるアミノ酸配列をポリペプチド鎖中に含む、ポリペプチド。
- ピキア・パストリス(Pichia pastoris)において得られたことを特徴とする、請求項1に記載のポリペプチド。
- 魚類及び甲殻類における成長を刺激するための、請求項1に記載のポリペプチドのいずれかを含む、組成物。
- 餌1kg当たり前記ポリペプチド4.8mgと同効率の投与量で魚類及び甲殻類における成長及び/又は疾病抵抗性を刺激するための飼料用製剤中における、請求項1に記載のポリペプチドを含むピキア・パストリス(Pichia pastoris)培養上清の使用。
- 水1リットル当たり前記ポリペプチド0.05から0.5mgの間の濃度において成長、生存率及び仔魚の品質を刺激するための魚類及び甲殻類での浸漬処置のための、請求項1に記載のポリペプチドを含むピキア・パストリス(Pichia pastoris)培養上清の使用。
- 魚類及び甲殻類の体液性自然免疫系を刺激するための、請求項1のポリペプチドのいずれかを含む、組成物。
- 観賞用魚類の処置のための、請求項1に記載のポリペプチドのいずれかを含む、組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20050135A CU23577A1 (es) | 2005-07-21 | 2005-07-21 | Polipéptidos estimuladores del crecimiento para uso en peces y crustáceos |
CU2005-0135 | 2005-07-21 | ||
PCT/CU2006/000006 WO2007009403A1 (es) | 2005-07-21 | 2006-06-23 | Polipéptidos estimuladores del crecimiento para uso en peces y crustáceos |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009501735A true JP2009501735A (ja) | 2009-01-22 |
JP4939536B2 JP4939536B2 (ja) | 2012-05-30 |
Family
ID=36956134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008521780A Expired - Fee Related JP4939536B2 (ja) | 2005-07-21 | 2006-06-23 | 魚類及び甲殻類における使用のための成長刺激ポリペプチド |
Country Status (18)
Country | Link |
---|---|
US (1) | US7919463B2 (ja) |
EP (1) | EP1911764B1 (ja) |
JP (1) | JP4939536B2 (ja) |
KR (1) | KR101190022B1 (ja) |
CN (1) | CN101253194B (ja) |
AT (1) | ATE439374T1 (ja) |
AU (1) | AU2006272216B2 (ja) |
BR (1) | BRPI0613621A2 (ja) |
CA (1) | CA2615833C (ja) |
CU (1) | CU23577A1 (ja) |
DE (1) | DE602006008478D1 (ja) |
ES (1) | ES2331627T3 (ja) |
IL (1) | IL188864A0 (ja) |
MX (1) | MX2008000962A (ja) |
MY (1) | MY145699A (ja) |
RU (1) | RU2008106612A (ja) |
WO (1) | WO2007009403A1 (ja) |
ZA (1) | ZA200800924B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102703483B (zh) * | 2012-06-08 | 2014-10-01 | 湖北肽洋红生物工程有限公司 | 罗非鱼重组口服蛋白tat-gh及制备方法和应用 |
JP6397429B2 (ja) * | 2013-11-28 | 2018-09-26 | 株式会社カネカ | 甲殻類の感染症の抑制方法 |
HK1218486A2 (zh) * | 2015-12-09 | 2017-02-17 | Ka Lun Alan Ng | 提高魚生長的手段和方法 |
CN107242161A (zh) * | 2017-06-05 | 2017-10-13 | 舟山市普陀兴海养殖优质种苗选育研究所 | 一种黑鲷鱼苗种培育技术 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030084469A1 (en) * | 2000-04-14 | 2003-05-01 | Chi-Yao Chang | Fish growth hormones |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0387457A1 (en) | 1989-01-06 | 1990-09-19 | Eurogentec S.A. | Recombinant fish hormone proteins |
DK0438200T3 (da) | 1990-01-16 | 2002-11-11 | Ct Ingenieria Genetica Biotech | Fremgangsmåde til ekspression af heterologe gener i gæren Pichia pastoris, ekspressionsvektorer og transformerede mikroorganismer |
US5695954A (en) | 1993-05-14 | 1997-12-09 | University Of Victoria Innovation & Development Corporation | DNA encoding two fish neuropeptides |
AU732058B2 (en) | 1997-03-24 | 2001-04-12 | Hih.Biocenter Inc. | Novel synthetic polypeptide |
EP1447181A1 (en) | 2003-02-11 | 2004-08-18 | Alto Danmark A/S | Lateral handgrip |
-
2005
- 2005-07-21 CU CU20050135A patent/CU23577A1/es not_active IP Right Cessation
-
2006
- 2006-06-23 CA CA2615833A patent/CA2615833C/en not_active Expired - Fee Related
- 2006-06-23 WO PCT/CU2006/000006 patent/WO2007009403A1/es active Application Filing
- 2006-06-23 AU AU2006272216A patent/AU2006272216B2/en not_active Ceased
- 2006-06-23 EP EP06753160A patent/EP1911764B1/en active Active
- 2006-06-23 KR KR1020087004003A patent/KR101190022B1/ko not_active IP Right Cessation
- 2006-06-23 RU RU2008106612/13A patent/RU2008106612A/ru unknown
- 2006-06-23 CN CN2006800313781A patent/CN101253194B/zh not_active Expired - Fee Related
- 2006-06-23 ES ES06753160T patent/ES2331627T3/es active Active
- 2006-06-23 BR BRPI0613621-4A patent/BRPI0613621A2/pt not_active IP Right Cessation
- 2006-06-23 JP JP2008521780A patent/JP4939536B2/ja not_active Expired - Fee Related
- 2006-06-23 AT AT06753160T patent/ATE439374T1/de not_active IP Right Cessation
- 2006-06-23 US US11/989,088 patent/US7919463B2/en not_active Expired - Fee Related
- 2006-06-23 DE DE602006008478T patent/DE602006008478D1/de active Active
- 2006-06-23 MX MX2008000962A patent/MX2008000962A/es active IP Right Grant
- 2006-07-04 MY MYPI20063173A patent/MY145699A/en unknown
-
2008
- 2008-01-17 IL IL188864A patent/IL188864A0/en unknown
- 2008-01-29 ZA ZA200800924A patent/ZA200800924B/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030084469A1 (en) * | 2000-04-14 | 2003-05-01 | Chi-Yao Chang | Fish growth hormones |
Also Published As
Publication number | Publication date |
---|---|
JP4939536B2 (ja) | 2012-05-30 |
CA2615833A1 (en) | 2007-01-25 |
ES2331627T3 (es) | 2010-01-11 |
ZA200800924B (en) | 2008-11-26 |
EP1911764B1 (en) | 2009-08-12 |
KR20080041656A (ko) | 2008-05-13 |
WO2007009403A1 (es) | 2007-01-25 |
AU2006272216B2 (en) | 2010-09-16 |
US20100167998A1 (en) | 2010-07-01 |
CN101253194A (zh) | 2008-08-27 |
EP1911764A1 (en) | 2008-04-16 |
AU2006272216A1 (en) | 2007-01-25 |
CU23577A1 (es) | 2010-09-30 |
KR101190022B1 (ko) | 2012-10-12 |
DE602006008478D1 (de) | 2009-09-24 |
BRPI0613621A2 (pt) | 2012-11-06 |
CA2615833C (en) | 2012-02-21 |
US7919463B2 (en) | 2011-04-05 |
ATE439374T1 (de) | 2009-08-15 |
MY145699A (en) | 2012-03-30 |
CN101253194B (zh) | 2011-09-28 |
IL188864A0 (en) | 2008-04-13 |
RU2008106612A (ru) | 2009-08-27 |
MX2008000962A (es) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4939536B2 (ja) | 魚類及び甲殻類における使用のための成長刺激ポリペプチド | |
KR101132185B1 (ko) | 수생 유기물 배영용 뉴로펩티드 | |
Acosta et al. | Tilapia somatotropin polypeptides: potent enhancers of fish growth and innate immunity | |
Lubis et al. | Enrichment of recombinant growth hormone in diet containing different levels of protein enhanced growth and meat quality of striped catfish (Pangasionodon hypophthalmus) | |
JP4195865B2 (ja) | 水生生物の成長促進および病気に対する抵抗力の向上のための方法 | |
WO2005115166A1 (en) | Method of enhancing growth and immunity of shrimp larvae using recombinant bovine growth hormone | |
US5122513A (en) | Fish growth using bovine placental lactogen | |
MX2008006702A (en) | Neuropeptides for the culture of aquatic organisms | |
Jia YongFang et al. | Pichia pastoris expressing recombinant Misgurnus anguillicaudatus growth hormone promotes the growth of M. anguillicaudatus larvae. | |
Mojer et al. | Effects of Some Dietary Additives on Growth Performance and Feed Efficiency of Young Common Carp Cyprinus carpio | |
JPH05184261A (ja) | サケ科の魚の、特に海水中での養殖に於けるソマトトロピンをベースとする改良方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090604 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120111 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120221 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120224 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150302 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |